File(s) under embargo

1

month(s)

9

day(s)

until file(s) become available

A new perspective in sepsis treatment: could RGD-dependent integrins be novel targets?

Sepsis is a life-threatening condition caused by the response of the body to an infection, and has recently been regarded as a global health priority because of the lack of effective treatments available. Vascular endothelial cells have a crucial role in sepsis and are believed to be a major target of pathogens during the early stages of infection. Accumulating evidence suggests that common sepsis pathogens, including bacteria, fungi, and viruses, all contain a critical integrin recognition motif, Arg-Gly-Asp (RGD), in their major cell wall-exposed proteins that might act as ligands to crosslink to vascular endothelial cells, triggering systemic dysregulation resulting in sepsis. In this review, we discuss the potential of anti-integrin therapy in the treatment of sepsis and septic shock.

Funding

Science Foundation Ireland (SFI) under Grant Number 13/CDA/2119

Enterprise Ireland (EI) under Grant Number CF-2017-0684-P

History

Comments

The original article is available at https://www.sciencedirect.com/

Published Citation

Nader D, Curley GF, Kerrigan SW. A new perspective in sepsis treatment: could RGD-dependent integrins be novel targets? Drug Discovery Today. 2020(12):2317-2325.

Publication Date

6 October 2020

PubMed ID

33035665

Department/Unit

  • Anaesthetics and Critical Care
  • Beaumont Hospital
  • School of Pharmacy and Biomolecular Sciences
  • Irish Centre for Vascular Biology

Research Area

  • Vascular Biology
  • Biomaterials and Regenerative Medicine
  • Immunity, Infection and Inflammation

Publisher

Elsevier BV

Version

  • Accepted Version (Postprint)